NovoCure (NVCR) Capital Expenditures Growth (1y) (2015 - 2026)
NovoCure (NVCR) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 129.01 Bn | 126.14 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.46 Bn | 67.01 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 48.40 Bn | 44.73 Bn | 1.29 Bn | 15.89% |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn | -11.95% |
| 7 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn | 106.98% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.46 Bn | 22.33 Bn | 2.07 Bn | -47.73% |
| 10 | NovoCure | 2.03 Bn | 1.59 Bn | 142.48 Mn | 26.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.07% |
| Mar 31, 2026 | -51.45% |
| Dec 31, 2025 | -45.25% |
| Sep 30, 2025 | -47.07% |
| Jun 30, 2025 | -52.07% |
| Mar 31, 2025 | -9.95% |
| Dec 31, 2024 | 31.10% |
| Sep 30, 2024 | 47.29% |
| Jun 30, 2024 | 65.14% |
| Mar 31, 2024 | 93.56% |
| Dec 31, 2023 | 6.06% |
| Sep 30, 2023 | 27.18% |
| Jun 30, 2023 | 67.78% |
| Mar 31, 2023 | 19.54% |
| Dec 31, 2022 | -54.95% |
| Sep 30, 2022 | 72.98% |
| Jun 30, 2022 | 57.79% |
| Mar 31, 2022 | 27.93% |
| Dec 31, 2021 | 147.86% |
| Sep 30, 2021 | -36.27% |